Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EAST-1 in axial spondyloarthritis
NL-OMON60523Phase 1Recruiting
- Sponsor
- Grey Wolf Therapeutics
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of ERAP inhibitor in axial spondyloarthritis (axSpA), sponsored by Grey Wolf Therapeutics. Primary endpoint: Primary endpoint(s). Started Dec 2025; status: recruiting.
02
Drugs
ERAP inhibitor
03
Conditions
axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on NL-OMON60523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60523.